Trial · NCT00609739
Cytosine Arabinoside and Mitoxantrone for Patients With Juvenile Myelomonocytic Leukemia Receiving Repeat Stem Cell Transplantation
NCT00609739, Phase 1, Phase 2, Terminated, Masonic Cancer Center, University of Minnesota; results first posted 2012-03-02
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Cytosine Arabinoside and Mitoxantrone for Patients With Juvenile Myelomonocytic Leukemia Receiving Repeat Stem Cell Transplantation. Trials, record NCT00609739. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00609739
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Cytosine Arabinoside and Mitoxantrone for Patients With Juvenile Myelomonocytic Leukemia Receiving Repeat Stem Cell Transplantation
- NCT number
- NCT00609739
- Status
- Terminated
- Phases
- Phase 1, Phase 2
- Enrollment
- 1 participants, actual
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Conditions
- Leukemia
- Interventions
- cyclosporine, cytarabine, filgrastim, methotrexate, methylprednisolone, mitoxantrone hydrochloride, allogeneic bone marrow transplantation, umbilical cord blood transplantation, Cis-Retinoic acid
- First posted
- 2008-02-07
- Last updated
- 2017-12-28
- Results first posted
- 2012-03-02
- Limitations and caveats
- Only 1 patient was enrolled (yr 1999) and later died (yr 2000). Study was terminated due to low accrual.
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Disease-free Survival | 1 year | Number of patients who were free of disease and alive at 1 year. |
| Secondary | Patients With Regimen-Related Toxicity | Up to 30 Days Post Study Treatment | Number of patients with adverse events related to treatment. |
| Secondary | Patients With Graft-Versus-Host-Disease | Up to 30 Days Post Study Treatment | Number of patients who exhibited acute and/or chronic graft-versus-host disease. |
| Secondary | Patients Who Relapsed | 1 Year | Number of patients whose disease relapsed. |
Source ClinicalTrials.gov
Outcomes4
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Disease-free Survival | 1 year | Participants | NUMBER | |
| SECONDARY | Patients With Regimen-Related Toxicity | Up to 30 Days Post Study Treatment | participants | NUMBER | |
| SECONDARY | Patients With Graft-Versus-Host-Disease | Up to 30 Days Post Study Treatment | participants | NUMBER | |
| SECONDARY | Patients Who Relapsed | 1 Year | participants | NUMBER |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Disease-free Survival | Cytarabine + Mitoxantrone | 0 | Participants | ||
| Patients With Regimen-Related Toxicity | Cytarabine + Mitoxantrone | 0 | participants | ||
| Patients With Graft-Versus-Host-Disease | Cytarabine + Mitoxantrone | 1 | participants | ||
| Patients Who Relapsed | Cytarabine + Mitoxantrone | 1 | participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Cytarabine + Mitoxantrone | 1 | |
| Overall Study | COMPLETED | Cytarabine + Mitoxantrone | 1 | |
| Overall Study | NOT COMPLETED | Cytarabine + Mitoxantrone | 0 |
Source ClinicalTrials.gov
Adverse events1
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| serious | Death | General disorders | Cytarabine + Mitoxantrone | 1 | 1 | 1 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Cytarabine + Mitoxantrone | ||
| Total, other adverse events | Cytarabine + Mitoxantrone | 0 | 1 |
| Total, serious adverse events | Cytarabine + Mitoxantrone | 1 | 1 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00609739
GET https://conductscience.org/api/trials/v1/NCT00609739/registered